Reconsidering Adult ADHD
neuroscienceCME Live and On DemandPremiere Date: Tuesday, September 1, 2015
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, September 1, 2016
Note: Credit Is No Longer Available
|Timothy E. Wilens, MD
Chief, Division of Child & Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School
|Doris M. Greenberg, MD
Associate Clinical Professor of Pediatrics
Mercer University School of Medicine
Memorial University Medical Center Children's Hospital
|Adelaide Sherwood Robb, MD
Chief, Division of Psychology and Behavioral Health
Director, Psychiatry Research
Center for Translational Science
Children's National Health Center
Professor, Psychiatry and Pediatrics
The George Washington University School of Medicine and Health Sciences
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder in adults in the United States, with a prevalence rate of 4.4%, making it second only to major depression. The National Comorbidity Survey Replication study revealed that only one in 10 adults identified as having ADHD were being treated for their ADHD, even though 45% had been in treatment for other mental health disorders during the previous year.1
Adult psychiatrists as well as many primary care providers are often not familiar with its presentation in childhood or adulthood. In addition, clinicians may be less familiar with how to obtain a good developmental history regarding the typical developmental abnormalities associated with the disorder since this is not typically done in an adult screening. Comorbid symptoms are common, and many of the associated symptoms of ADHD are easily understood within the framework of mood disorders with which adult psychiatrists are more familiar.
The educational content for this neuroscienceCME Live and On Demand webcast will be drawn from both the evidence and interviews with a panel of adult patients with ADHD to reflect the challenges faced in managing their disease. Faculty will use these insights to address key goals to better screen adult patients for ADHD and develop a comprehensive treatment strategy.
- Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. PMID: 1658544.
At the end of this CE activity, participants should be able to:
- Screen adult patients for a history of ADHD and evaluate for ADHD symptoms especially as comorbid with other disorders.
- Implement a comprehensive treatment strategy that is personalized with patient input and includes both pharmacological and nonpharmacological approaches to the management of adult ADHD.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Evaluate a screening plan for adult patients for a history of ADHD and evaluation of symptoms.
- Review a comprehensive treatment strategy that is personalized with patient input and includes both pharmacological and non-pharmacological approaches to the management of adult ADHD.
This educational activity is supported by an independent medical educational grant from Shire.
Physicians, physician assistants, nurse practitioners, nurses, pharmacists, social workers, case managers, and other health care professionals interested in adult ADHD.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
NASW Credit (Social Workers):
This Program is approved by the National Association of Social Workers (Approval # 886407722-3048) for 1.5 continuing education contact hours.
CCMC Credit (Certified Case Managers):
This program has been approved for 1.5 CE contact hours by The Commission for Case Manager Certification (CCMC). Activity Code: I00016636, Approval #: 150002559
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-15-022-H01-P (recorded programs)
Activity Type: knowledge-based
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wilens has disclosed that he has received research grants from the National Institue on Drub Abuse. He serves as a consultant to Euthymics Bioscience/Neurovance; Ironshore Pharmaceuticals & Development, Inc.; (NIDA/NIH) National Institute on Drug Abuse; Sunovion Pharmaceuticals Inc.; and Tris Pharma Inc.
Dr. Greenberg has disclosed that she is a stock shareholder (directly purchased) in Abbott; AbbVie Inc.; GlaxoSmithKline; Johnson & Johnson; Novartis; and Novo Nordisk.
Dr. Robb has disclosed that she has received research grants from Forest Laboratories, LLC; Lundbeck; National Institute of Neurological Disorders and Stroke (NINDS); Pfizer Inc.; Sunovion Pharmaceuticals Inc.; and SyneuRx. She serves as a consultant to Actavis Inc.; Ironshore Pharmaceuticals & Development, Inc.; Lundbeck; and Takeda Pharmaceuticals U.S.A., Inc. She is a stock shareholder (directly purchased) in IRA since 2001-2003 Eli Lilly and Company; GlaxoSmithKline ; Pfizer Inc.; and Johnson & Johnson. She has other financial or material support from Neuronetics on DSMB.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).